Biotech: Page 5
-
Permission granted by Actio Bio
A startup banks $66M to pursue ‘inclusive precision medicine’
With backers such as Regeneron’s venture arm, Actio Biosciences is working on medicines that counter a wide range of disease-causing genetic mutations in conditions like epilepsy and Charcot-Marie-Tooth disease.
By Gwendolyn Wu • June 18, 2025 -
Daniel Tadevosyan via Getty Images
FDA clears CSL’s swelling disease drug; Regeneron loses 23andMe auction
The agency cleared CSL’s hereditary angioedema drug days after “resource constraints” delayed a rival medicine. Elsewhere, Intellia revealed new data and Lilly beefed up an online service offering access to Zepbound.
By BioPharma Dive staff • June 17, 2025 -
Explore the Trendline➔
National Institutes of Allergy and Infectious Diseases. (2016). "Human natural killer cell" [Micrograph]. Retrieved from Flickr.
TrendlineCell therapy
The continued emergence of CAR-T therapy has fueled research into next-generation approaches and new applications, such as its use in autoimmune diseases.
By BioPharma Dive staff -
Naeblys via Getty Images
Roche, waving off study failures, commits to Phase 3 trials for Parkinson’s drug
The Swiss drugmaker said it was “encouraged” by the signs of effectiveness of the drug, developed by biotech Prothena, showed in two earlier studies that missed their main goals.
By Jonathan Gardner • June 16, 2025 -
MadamLead via Getty Images
Sage, following setbacks, to sell to Supernus for $561M
In what one analyst described as an “unremarkable” outcome, the brain drug developer is being acquired for just $8.50 per share, plus non-guaranteed additional payouts, after a series of stumbles that depressed its stock price.
By Delilah Alvarado • June 16, 2025 -
Kayla Bartkowski via Getty Images
FDA to miss approval deadline for Kalvista drug due to ‘resource constraints’
A “heavy workload” and “limited resources” have left the agency unable to meet a June 17 deadline to approve a therapy Kalvista has been developing for hereditary angioedema.
By Ben Fidler • June 16, 2025 -
Courtesy of CureVac AG
BioNTech buys mRNA, courtroom rival CureVac in all-stock deal
Valued at $1.25 billion, the deal expands BioNTech’s cancer drug portfolio and heads off royalty costs it could have owed CureVac in ongoing patent litigation.
By Jonathan Gardner • June 13, 2025 -
Jacob Bell/BioPharma Dive
VaccinesModerna wins FDA OK to widen use of RSV vaccine
The agency’s decision to clear Moderna’s shot for use in certain younger adults is a much-needed win for a company that’s been significantly impacted by the recent changes in FDA and HHS leadership.
By Delilah Alvarado • June 13, 2025 -
Daniel Tadevosyan via Getty Images
AstraZeneca forms an AI deal in China; Third Harmonic advances liquidation plans
AstraZeneca could spend up to $5.3 billion in a deal to develop oral medicines with CSPC Pharmaceutical. Elsewhere, Insmed cashed in on a stock surge and Third Harmonic kicked off a drug auction.
By Ben Fidler • June 13, 2025 -
Courtesy of EQT Life Sciences
SpliceBio lands $135M for a new kind of eye gene therapy
The startup, which is backed by the venture arms of Sanofi, Roche and Novartis, is using dual adeno-associated viruses to help overcome the packaging constraints of current genetic medicines.
By Gwendolyn Wu • June 11, 2025 -
Daniel Tadevosyan via Getty Images
Insmed surges on lung drug data; Recursion cuts staff
Insmed shares rocketed on results for a pulmonary arterial hypertension drug that exceeded Wall Street expectations. Elsewhere, Recursion is laying off 20% of its workforce and Gilead halted several HIV studies.
By BioPharma Dive staff • June 11, 2025 -
SciePro via Getty Images
FDA clears Nuvation lung cancer drug, setting up battle with Bristol Myers and Roche
The drug, Ibtrozi, will now vie for market share in an indication where multiple large pharmaceutical companies have already struggled to grow sales.
By Ben Fidler • June 11, 2025 -
Maximusnd via Getty Images
Scorpion, fresh off Lilly deal, spins out startup Antares
Five months after selling a cancer drug to Lilly for up to $2.5 billion, Scorpion has debuted a successor company led by its former management team to chase “previously inaccessible” drug targets.
By Ben Fidler • June 10, 2025 -
Courtesy of National Resilience; Business Wire
National Resilience, a well-funded manufacturing startup, to scale back operations
The startup, which has raised more than $2 billion in funding to aid young biotechs with drug production, said its “capacity expansion has outpaced industry demand.”
By Gwendolyn Wu • June 10, 2025 -
MadamLead via Getty Images
Biotech zombiesConcentra to acquire Elevation in bid to eliminate another biotech ‘zombie’
The offer is the latest in a series of deals by Concentra, an entity controlled by Tang Capital Partners, to buy struggling biotechs and shut them down.
By Ben Fidler • June 9, 2025 -
Spencer Platt via Getty Images
Obesity drugsMetsera shares climb on early data for amylin-targeting obesity shot
Early-stage study results suggest that a single shot of the company’s therapy, which works differently than GLP-1 medicines, might have effects that last at least four weeks.
By Jonathan Gardner • Updated June 9, 2025 -
Courtesy of Omada Health
Omada goes public in second recent digital health IPO
The chronic condition management company’s debut comes weeks after another digital health company, Hinge Health, went public. The IPOs are a “promising bellwether” for the sector, one expert said.
By Emily Olsen • June 9, 2025 -
Daniel Tadevosyan via Getty Images
Otsuka tops Vera with kidney drug data; Regenxbio sinks on Duchenne update
Late-stage results Otsuka presented in IgA nephropathy triggered a sell-off in Vera shares. Elsewhere, investors scrutinized Regenxbio’s Duchenne data and a brain drug study failed.
By BioPharma Dive staff • June 6, 2025 -
Jian Fan via Getty Images
Immune resetCullinan doubles down on bispecifics for autoimmune disease with Genrix deal
The deal gives Cullinan T cell engagers aimed at BCMA and CD19, which drugmakers are exploring as possible targets for antibody- and cell-based drugs for inflammatory conditions.
By Kristin Jensen • June 5, 2025 -
interstid via Getty Images
Biotech funding plummets as Trump policies unnerve investors: Jefferies
The investment bank says funding was down 57% last month, to $2.7 billion, and argues the new administration’s FDA restructuring, NIH cuts and drug pricing rules are “exacerbating” the decline.
By Jacob Bell • June 4, 2025 -
Daniel Tadevosyan via Getty Images
Regeneron makes obesity push; Atai, Alto ink brain drug deals
Regeneron licensed a weight loss drug and revealed study data for a pair of muscle-preserving medicines. Elsewhere, two neuroscience biotechs cut deals and Bluebird officially went private.
By BioPharma Dive staff • June 4, 2025 -
Permission granted by Jen Randall / Kymera Therapeutics
Kymera, with new data, takes early step toward a Dupixent-like pill
Phase 1 results disclosed Monday indicate the company’s protein-degrading drug can affect a tough-to-reach target called STAT6 that’s implicated in many autoimmune conditions.
By Gwendolyn Wu • June 2, 2025 -
Jian Fan via Getty Images
Vera drug scores in closely watched study in rare kidney disease
Phase 3 results revealed Monday led shares to surge and should yield an approval application in IgA nephropathy, a competitive corner of drug research, later this year.
By Ben Fidler • June 2, 2025 -
Sean Gallup via Getty Images
Bristol Myers allies with BioNTech on bispecific cancer drug
The oncology giant will pay $1.5 billion to co-develop a BioNTech drug that targets the proteins PD-L1 and VEGF, following Merck and Pfizer into what’s become a competitive development race.
By Ned Pagliarulo • June 2, 2025 -
Andrey_Popov / shutterstock.com
Sponsored by NateraGenetics is a missing link in kidney disease drug development
Genetic research is driving progress in kidney disease drug discovery.
June 2, 2025 -
wildpixel via Getty Images
New Summit data could slow US approval plans for PD-1/VEGF drug
Ivonescimab helped cut the risk of lung tumor progression in half in a multi-country Phase 3 trial. But it hasn’t yet clearly extended survival, which will be necessary to support an FDA submission.
By Ben Fidler • May 30, 2025
Previous
